Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03755128 · ClinicalTrials.gov registry record
A Study to Characterize the Clinical Course of Pregnant Women and Children at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn
A clinical trial, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 17
- Enrollment target
NCT03755128 is a clinical trial that has completed, run by Janssen Research & Development. The registered enrollment target is 17 participants.
The verdict
NCT03755128 has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 17 participants
- Enrollment target
Study Summary
The primary purpose of the study is to characterize the current standard of care, clinical course, and outcomes of pregnant women and their offspring at high risk for early onset severe hemolytic disease of the fetus and newborn (EOS-HDFN).
Interventions
- OTHER No intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-01-16 |
| Est. Completion | 2023-09-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03755128
The ClinicalTrials.gov registry entry for NCT03755128 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No intervention is the first listed.
NCT03755128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03755128 about?
NCT03755128 is a clinical study titled "A Study to Characterize the Clinical Course of Pregnant Women and Children at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn". The primary purpose of the study is to characterize the current standard of care, clinical course, and outcomes of pregnant women and their offspring at high risk for early onset severe hemolytic disease of the fetus and newborn (EOS-HDFN).
What is the current status of trial NCT03755128?
This trial is currently completed. The enrollment target is 17 participants. The study started on 2019-01-16. Estimated completion is 2023-09-22.
What interventions are being tested in trial NCT03755128?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT03755128?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.